<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202003</url>
  </required_header>
  <id_info>
    <org_study_id>TJ011133AML102</org_study_id>
    <nct_id>NCT04202003</nct_id>
  </id_info>
  <brief_title>A Phase I/IIa Clinical Research of TJ011133 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (r/r AML)</brief_title>
  <official_title>A Multi-center, Open, Single-arm, Phase I/IIa Clinical Research to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 in the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia (r/r AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma HongKong Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma HongKong Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, open, single-arm, Phase I/IIa clinical research to evaluate the safety,
      tolerance, pharmacokinetics, pharmacodynamics and preliminary efficacy of TJ011133 in the
      treatment of patients with relapsed or refractory acute myeloid leukemia (r/r AML)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2020</start_date>
  <completion_date type="Anticipated">December 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities(DLT)</measure>
    <time_frame>28days after first dose</time_frame>
    <description>To evaluate the safety and tolerance of TJ011133 monotherapy in patients with r/r AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerable dose(MTD)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To explore the maximum tolerable dose (MTD) of TJ011133 monotherapy for patients with r/r AML, the recommended phase II dose (RP2D) and the optimal dosage regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Recommended phase II dose (RP2D)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>TJ011133</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ011133 is tentatively administered once a week for a treatment cycle every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ011133</intervention_name>
    <description>TJ011133 is tentatively administered once a week for a treatment cycle every 28 days</description>
    <arm_group_label>TJ011133</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be ≥18 and ≤70 years old when signing the informed consent, with no
             limitation of gender;

          -  Subjects must be patients with pathologically confirmed acute myeloid leukemia (AML)
             and complying with the World Health Organization (WHO) criteria for classification,
             excluding those with acute promyelocytic leukemia;

          -  Subjects must be patients with recurrent or refractory *AML with no further
             appropriate routine therapy;

          -  Subjects must be willing to provide available diagnostic evidence prior to treatment
             or undergo bone marrow aspiration and biopsy, and willing to undergo marrow aspiration
             and biopsy after accepting research and treatment.

          -  Eastern Cooperative Oncology Group(ECOG) score is 0 - 2;

          -  Expected survival ≥12 weeks;

          -  White blood cell count (WBC) is ≤ 25 x103/µL within 7 days before the first
             administration (hydroxyurea or leukocyte depletion is allowed to meet this standard);

          -  Subjects have been recovered from the toxicity of previous anti-leukemia treatments
             (according to NCI Common Terminology Criteria for Adverse Events (CTC AE) 5.0 ≤ 1
             level, except hair loss);

          -  Subjects must have full liver function, renal function and coagulation function. The
             laboratory tests within 7 days before the first administration should meet the
             following requirements:

          -  Subjects must give informed consent before the test and sign written consent
             voluntarily by themselves (or their legal representatives). Subjects or their legal
             representatives should be able to communicate well with investigators and agree to
             complete the test according to the scheme.

        Exclusion Criteria:

          -  Subjects must be excluded if meeting any of the following criteria:

          -  Subjects have previously received treatment with other drugs targeting CD47;

          -  Subjects have previously received Chimeric Antigen Receptor T-Cell (CAR-T ) therapy;

          -  Subjects have previously received treatment with PD1 or PDL1 antibodies;

          -  Subjects have previously received allogenic stem cell transplant, or received
             autologous stem cell transplant within 3 months before administration of the research
             drug;

          -  Subjects have received chemotherapy, immunotherapy, radiotherapy and large-scale
             surgery within 4 weeks before the first administration;

          -  Subjects have received the vaccine within 4 weeks before the first administration
             and/or after planing to participate in the trial;

          -  Subjects have received clinical trial medication within four weeks before first
             administration or are participating in other interventional clinical trials;

          -  Subjects are known to have hereditary or acquired hemorrhagic diseases;

          -  Subjects meet any of the following cardiac function criteria:

          -  Subjects have hypertension unable to be well controlled by medication (systolic blood
             pressure ≥140mmHg or diastolic blood pressure≥90mmHg in resting state);

          -  Subjects suffer from diseases requiring long-term treatment with systemic steroids or
             other immunosuppressive agents. However, patients who use physiologically alternative
             doses of hydrocortisone or its equivalent dose (Annex 6) may be considered for
             enrollment: hydrocortisone up to 20mg (or 5 mg of pernisin) in the morning, and
             hydrocortisone up to 10mg (or 2.5 mg of pernisin) at night;

          -  Subjects are known to have central nervous system (CNS) attacks;

          -  Subjects are known to have HIV infection (anti-HIV positive), active hepatitis B
             (HBsAg positive, or HBcAb positive and HBV-DNA PCR positive), or active hepatitis C
             (anti-HCV positive and HCV-RNA PCR positive), or syphilis (anti-TP positive);

          -  Subjects have a history of solid organ transplantation;

          -  Subjects are receiving other antineoplastic treatments, including but not limited to
             chemotherapy, biotherapy, immunotherapy, hormone therapy and treatment by Chinese
             herbs while planning to participate in the trial;

          -  Subjects have a history of autoimmune diseases or active autoimmune diseases;

          -  Subjects still have uncontrolled active infections;

          -  Subjects have severe electrolyte disorders that cannot be corrected;

          -  Subjects have a history of other malignant tumors, except for clinically cured
             malignant tumors (relapse free for at least 5 years), cured in situ cancers and skin
             cancers of non-malignant melanoma;

          -  Subjects have a history of psychotropic drug abuse and are unable to quit or have
             mental disorders, or are judged be the investigators to have concomitant diseases that
             seriously endanger patients' safety or hinder the patients from completion of the
             test;

          -  Subjects are women during pregnancy or lactation, or women and men with fertility
             planning;

          -  The investigators believe that patients have other factors that may affect the results
             of the research and interfere with their full participation in the research, including
             previous or existing health conditions or abnormal medical or laboratory examination,
             or put them at high risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianxiang Wang, Doctor</last_name>
    <phone>022-23909278</phone>
    <email>wangjx@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Huang, Master</last_name>
    <phone>021-60575756</phone>
    <email>wei.huang@i-mabbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Li, doctor</last_name>
      <email>lijian@pumch.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University International Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102206</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bin Jiang, doctor</last_name>
      <email>jiangbin1442@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianxiang Wang, Doctor</last_name>
      <email>wangjx@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Junyuan Qi, Doctor</last_name>
      <email>qijy@ihcams.ac.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

